https://www.selleckchem.com/pr....oducts/-r-s--3-5-dhp
We reviewed WT molecular features, ongoing/planned early phase trials and explored available knowledge on organoid technology. The key messages were (1) relapsed WT should undergo whenever possible thorough molecular characterization and be enrolled in protocols or trials with systematic data collecting and reporting; (2) WT displays few known 'actionable' targets and currently no novel agent has appeared promising; (3) we need to improve the enrolment rate of WT candidates in early phase trials especially for the relatively smal
Like
Comment
Share
